© Copyright 2025 American Medical Association. All rights reserved.
Molecular genetic testing is performed to identify a specific mutation of the FLT3 (fms-related tyrosine kinase 3) gene associated with acute myeloid leukemia (AML). This gene analysis focuses on internal tandem duplication (ITD) variants found in exons 14 and 15 of the FLT3 gene. Genetic testing for this mutation is considered the standard of care for all patients diagnosed with AML, as it plays a crucial role in determining the appropriate therapeutic approach. The presence or absence of the FLT3 gene mutation can significantly influence treatment decisions, helping to predict the potential benefits of specific therapies and the associated risks of recurrence or disease progression. Notably, the FLT3 mutation is present in at least 25% of all patients diagnosed with AML, although its presence does not necessarily correlate with a poor cure rate. AML is recognized as the most common type of acute leukemia, predominantly affecting men over the age of 65, while it is rarely diagnosed in individuals under the age of 40. The FLT3 gene encodes a class 3 tyrosine kinase receptor that is integral to the regulation of hematopoiesis. This receptor is activated when the FLT3 ligand binds to its extracellular domain, leading to the formation of homodimers in the plasma membrane. This process triggers autophosphorylation of the receptor, which continues to activate cytoplasmic effector molecules involved in the pathways of apoptosis, proliferation, and differentiation of hematopoietic cells within the bone marrow. Mutations in the FLT3 gene can lead to the development of acute myeloid leukemia as well as acute lymphoblastic leukemia.
© Copyright 2025 Coding Ahead. All rights reserved.
The FLT3 gene analysis is indicated for patients diagnosed with acute myeloid leukemia (AML). This testing is essential for determining the presence of specific mutations that can influence treatment decisions and prognostic outcomes.
The procedure for conducting the FLT3 gene analysis involves several key steps to ensure accurate results. First, a sample of the patient's blood or bone marrow is collected, which contains the hematopoietic cells necessary for testing. Next, the sample undergoes processing to isolate the DNA, which is then subjected to molecular genetic testing techniques specifically designed to detect internal tandem duplication (ITD) variants in exons 14 and 15 of the FLT3 gene. This may involve polymerase chain reaction (PCR) amplification followed by sequencing or other methods to confirm the presence of the mutation. Once the analysis is complete, the results are interpreted by a qualified healthcare professional, who will assess the implications of the findings for the patient's treatment plan and prognosis.
After the FLT3 gene analysis is completed, the patient may receive counseling regarding the results and their implications for treatment. If a mutation is detected, the healthcare provider will discuss potential therapeutic options that may be more effective based on the genetic findings. Additionally, the patient may be monitored for any signs of disease progression or recurrence, as the presence of the FLT3 mutation can influence long-term management strategies. Follow-up appointments may be scheduled to reassess the patient's condition and adjust treatment plans as necessary.
| Short Descr | FLT3 GENE | Medium Descr | FLT3 GENE ANALYSIS INTERNAL TANDEM DUP VARIANTS | Long Descr | FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia), gene analysis; internal tandem duplication (ITD) variants (ie, exons 14, 15) | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Service Paid under Fee Schedule or Payment System other than OPPS | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T1H - Lab tests - other (non-Medicare fee schedule) | MUE | 1 | CCS Clinical Classification | 234 - Pathology |
| 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | GC | This service has been performed in part by a resident under the direction of a teaching physician | 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | 26 | Professional component: certain procedures are a combination of a physician or other qualified health care professional component and a technical component. when the physician or other qualified health care professional component is reported separately, the service may be identified by adding modifier 26 to the usual procedure number. | 77 | Repeat procedure by another physician or other qualified health care professional: it may be necessary to indicate that a basic procedure or service was repeated by another physician or other qualified health care professional subsequent to the original procedure or service. this circumstance may be reported by adding modifier 77 to the repeated procedure or service. note: this modifier should not be appended to an e/m service. | GA | Waiver of liability statement issued as required by payer policy, individual case | GW | Service not related to the hospice patient's terminal condition | GZ | Item or service expected to be denied as not reasonable and necessary | Q1 | Routine clinical service provided in a clinical research study that is in an approved clinical research study | QW | Clia waived test | XU | Unusual non-overlapping service, the use of a service that is distinct because it does not overlap usual components of the main service |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2015-01-01 | Changed | Description Changed |
| 2012-01-01 | Added | Added |
Get instant expert-level medical coding assistance.